EUVIMEDEUVIMED entdecken
Crossref

Two New Drugs for Gonorrhea

The Medical Letter on Drugs and Therapeutics · 02.03.2026 · 68 (1750) · 41-43

DOI: 10.58347/tml.2026.1750a ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 02.03.2026. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The FDA has approved two antibiotics, gepotidacin (Blujepa — GSK) and zoliflodacin (Nuzolvence — Entasis), for oral treatment of uncomplicated urogenital gonorrhea in patients ≥12 years old.1 Gepotidacin is approved for use in persons weighing ≥45 kg who have limited or no alternative treatment options; it was approved in 2025 for treatment of uncomplicated urinary tract infection in females.2 Zoliflodacin is approved for use in persons weighing ≥35 kg. Neither drug is indicated for treatment of rectal or pharyngeal gonorrhea.

Schlagwörter

Stichwörter der Autor:innen

BlujepaNeisseria gonorrhoeaeNuzolvenceadverse effectsantibacterialsazithromycincefiximeceftriaxonecephalosporinsdosagedoxycyclinedrug interactionsefficacyfluoroquinolonesgentamicin

Zitieren

APA

(2026). Two New Drugs for Gonorrhea. The Medical Letter on Drugs and Therapeutics, 68(1750), 41-43. https://doi.org/10.58347/tml.2026.1750a

Vancouver

Two New Drugs for Gonorrhea. The Medical Letter on Drugs and Therapeutics. 2026;68(1750):41-43. doi:10.58347/tml.2026.1750a

BibTeX
@article{euvimed2026,
  title = {Two New Drugs for Gonorrhea},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2026},
  volume = {68},
  number = {1750},
  pages = {41--43},
  doi = {10.58347/tml.2026.1750a}
}
Kostenlos starten →